GALLIUM: MRD response correlates with outcomes in follicular lymphomaJanuary 31, 2019Lymphoma & Plasma Cell Disorders
Applying ECHELON-2 results to clinical practiceJanuary 31, 2019Aggressive LymphomasLymphoma & Plasma Cell Disorders
FDA approves ibrutinib plus obinutuzumab for CLL/SLLJanuary 28, 2019Leukemia, Myelodysplasia, Transplantation
EC approves blinatumomab for MRD-positive BCP-ALLJanuary 25, 2019Leukemia, Myelodysplasia, TransplantationALL
Umbralisib gains FDA breakthrough designation for MZLJanuary 25, 2019Lymphoma & Plasma Cell Disorders
Novel bispecific CAR shows promise in B-cell malignanciesJanuary 25, 2019Aggressive LymphomasLymphoma & Plasma Cell DisordersTransplantation
Uninterrupted ibrutinib with CAR T could improve CLL outcomesJanuary 25, 2019Leukemia, Myelodysplasia, Transplantation
Combo treatment may improve quality of life in CTCLJanuary 24, 2019Lymphoma & Plasma Cell DisordersAggressive Lymphomas
Are single agents better than chemo for relapsed/refractory PTCL?January 24, 2019Lymphoma & Plasma Cell DisordersAggressive Lymphomas
Four-drug combo shows durable responses in relapsed/refractory lymphomasJanuary 19, 2019Aggressive Lymphomas
